5 results
Primary objective of the study is the assessment of the dose limiting toxicity (DLT) and the maximal tolerated dose (MTD) of capecitabine and mitomycin-C with concomitant SIBRT in patients with locally advanced anal carcinoma.Secondary objectives…
To determine whether administration of exogenous surfactant using a minimally-invasive technique improves outcome in preterm infants 25-28 weeks gestation treated with continuous positive airway pressure (CPAP).
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.
*In the phase Ib study: to assess the feasibility and safety of the addition of nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder.*In the phase II study: to assess the impact of the addition of the addition of nivolumab…